Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study.
AIMS General population distributions of lipoprotein(a) (Lp(a)) are well-characterized. However, less is known about its distributions and associated event rates within high-risk populations, including individuals with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and varying levels of su...